The Evolving Hemophilia Managed Care and Specialty Pharmacy Environment: Recommendations for a New Health Care Ecosystem Web Activity

• Release Date: November 5, 2015
• Expiration Date: May 5, 2017
• Estimated Time to Complete Activity: 1.25 hours
• Compatible with all modern browsers and mobile devices

DISTINGUISHED FACULTY

Edmund Pezalla, MD National Medical Director for Pharmacy Policy and Strategy Aetna, Inc. Click here for biography

Vanita K. Pindolia, PharmD, BCPS Vice President, Ambulatory Clinical Pharmacy Programs_PCM Henry Ford Health System/Health Alliance Plan of Michigan Click here for biography

Michael Tarantino, MD Professor of Pediatrics, Division of Pediatric Hematology/Oncology University of Illinois College of Medicine Medical Director Bleeding & Clotting Disorders Institute Click here for biography Michael Zeglinski, RPh Senior Vice President, Specialty Pharmacy OptumRx®/BriovaRx® Click here for biography

Target Audience

• Medical directors and pharmacy directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for patients with hemophilia including: physicians, pharmacists, registered nurses, and case managers

Statement of Need/Program Overview

Hemophilia is an expensive chronic condition with total annual costs that can average $250,000 or more for severe patients. Optimal outcomes requires a collaborative and coordinated patient experience. The collaborative team can include an insurer, Hemophilia Treatment Center (HTC), and specialty pharmacy. Specialty pharmacy services can support patient adherence to treatment and assist physicians, plans and employers in meeting clinical and/or financial goals.

This activity will emphasize the need for well-coordinated treatment management, the importance of understanding effective ways of using available treatments, and the importance of collaboration among all stakeholders.

Educational Objectives
After completing this activity, the participant should be better able to:

• Describe current and evolving strategies used by managed care organizations (MCOs) and specialty pharmacy providers to facilitate high quality care for members with hemophilia
• Summarize the most recent clinical recommendations for the treatment of patients with hemophilia, including prophylactic factor replacement
• Explain the severe complication of hemophilia treatment known as inhibitor development, and its significant clinical and economic consequences
• Identify processes for MCOs and specialty pharmacy providers to improve communications with HTCs
• Apply collaborative methods that enable the benefits of the comprehensive care model provided by HTCs to be realized by multiple hemophilia stakeholders including MCOs and specialty pharmacy providers
• Provide accurate and appropriate counsel as part of the managed care treatment team
• Provide appropriate care and counsel for patients and their families

ACCREDITATION

Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine, the National Hemophilia Foundation, and Impact Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Pharmacist Continuing Education
Accreditation Statement

	Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
Postgraduate Institute for Medicine designates this continuing education activity for 1.3 contact hours (0.13 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – 0809-9999-15-272-H01-P)

Type of Activity
Application

Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

Nursing Continuing Education

Credit Designation
This educational activity for 1.3 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

A statement of credit will be issued only upon receipt of a completed activity evaluation form.

DISCLOSURE OF CONFLICTS OF INTEREST

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy.  PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT

There are no fees for participating and receiving CME/CE credit for this activity. During the period November 5, 2015 through May 5, 2017, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 75% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA

Internet

FEE INFORMATION

There is no fee for this educational activity.